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Background: European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) criteria have been
developed to increase diagnostic yield, but their predictive value is limited. We investigated the incremental
diagnostic value of faecal calprotectin to EPAGE criteria.
Methods: In a post-hoc analysis of a prospective study, EPAGE criteria were applied to 298 of 575 (51.8%) patients
who had undergone esophagogastroduodenoscopy (EGD), colonoscopy or both for abdominal complaints at the
Division of Gastroenterology & Hepatology at the University Hospital Basel in Switzerland. Faecal calprotectin was
measured in stool samples collected within 24 hours before the investigation using an enzyme-linked immunosorbent
assay. Final endoscopic diagnoses were blinded to calprotectin values.
Results: Of 149 EGDs and 224 colonoscopies, 17.6% and 14.7% respectively were judged inappropriate by EPAGE criteria.
Appropriate or uncertain indications revealed more endoscopic findings in both EGD (46.3% vs. 23.1%, P = 0.049) and
colonoscopy (23.6% vs. 6.1%, P = 0.041) than inappropriate indications. Median calprotectin levels were higher (81.5 μg/g,
interquartile range 26-175, vs. 10 μg/g, IQR 10–22, P < 0.001) and testing was more often positive (>50 μg/g) in patients
with endoscopic findings, both in EGD (58.2% vs. 33.0%, P = 0.005) and in colonoscopy (57.3% vs. 7.4%, P < 0.001). The use
of faecal calprotectin in addition to EPAGE criteria improved the risk reclassification of patients by endoscopic findings.
The calculated net reclassification index was 37.8% (P = 0.002) for EGD and 110.9% (P <0.001) for colonoscopy, thus
improving diagnostic yield to 56.8% and 70.2%, respectively.
Conclusions: The use of faecal calprotectin in addition to EPAGE criteria improved diagnostic yield in patients with
abdominal complaints.
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Abdominal complaints are commonly seen in patients in
clinical practice and many undergo endoscopy for fur-
ther evaluation. However, symptoms may arise from a
variety of disorders, including functional dyspepsia and
irritable bowel syndrome, and the potential risk of* Correspondence: emanuel.burri@ksbl.ch
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unless otherwise stated.invasive procedures must be balanced against the benefit
of detecting a significant organic disease.
Patient selection based on symptoms alone is unfortu-
nately not reliable, both for patients with dyspepsia [1]
and with lower abdominal symptoms [2]. Around half of
patients with peptic ulcer disease or esophagitis at en-
doscopy will be misclassified when presenting with epi-
gastric pain [1]. Accordingly, major pathologies (ulcer,
malignancy) are found in only a minority of dyspeptic
patients [3]. Similarly, in average-risk patients with non-
specific lower abdominal symptoms, the overall yield ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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risk screening population. For patients reporting hema-
tochezia, 66% of patients <45 years will have normal
findings and only 17% will show significant lesions [4].
There is clearly a need for better selection criteria to de-
cide on endoscopy and improve the diagnostic yield in
patients with abdominal complaints.
The European Panel on the Appropriateness of Gastro-
intestinal Endoscopy (EPAGE) has published a series of
guidelines on the appropriate use of endoscopy for a variety
of clinical scenarios (www.epage.ch) [5,6]. Using these
criteria, inappropriate indications for esophagogastroduode-
noscopy (EGD) or colonoscopy have been reported in
10.5 – 39% [7-18], depending on patient selection. Accord-
ingly, EGD judged appropriate or uncertain by EPAGE
guidelines yielded significantly more relevant lesions (60%)
than did those judged to be inappropriate (37%) [7]. These
findings were confirmed by some studies [15,16] but not by
all [19]. In patients undergoing screening colonoscopy,
14.4% had significant findings and compared to inappropri-
ate indications, the odds ratio of endoscopic findings for ap-
propriate or uncertain indications was 3.2 (95%CI 1.1-17)
[10]. Similar results have been reported in consecutive pa-
tients referred for diagnostic colonoscopy [9,11,12,17,19].
The efficient use of endoscopic procedures is paramount to
ensure high-quality cost-effective medical care. However,
the low specificity of current guidelines of appropriateness
substantially reduces the predictive value of relevant endo-
scopic findings. The use of a diagnostic test in addition to
appropriateness criteria might therefore be beneficial by in-
creasing diagnostic yield.
Calprotectin is an abundant, calcium- and zinc-
binding protein found mainly in neutrophils. It corre-
lates well with neutrophil infiltration of the intestinal
mucosa and when measured in faeces, it is considered as
an established biological marker of intestinal inflamma-
tion throughout the gastrointestinal tract. It has proven
highly useful for the identification of inflammatory
bowel disease [20] and for distinguishing between or-
ganic and functional disorders of the colon [21] and
similar the upper intestinal tract although less perfor-
mant [22].
The goal of this study was thus to investigate if the use
of faecal calprotectin testing in combination with guide-
lines of appropriateness would improve the diagnostic
yield of endoscopic procedures. To do so, we investi-
gated a large population of unselected patients with ab-
dominal discomfort referred for endoscopy.
Methods
Setting and participants
We performed a post-hoc analysis of a prospective study to
investigate the value of guidelines of appropriateness and
faecal calprotectin levels on diagnostic yield in patientsundergoing gastrointestinal endoscopy for abdominal dis-
comfort [22]. The study was conducted at the Division of
Gastroenterology & Hepatology of the University Hospital
Basel in Switzerland. A total of 575 patients with abdominal
discomfort referred for either EGD or colonoscopy were
enrolled in the study. Patients <18 years old were excluded.
The study was carried out according to the principles of
the Declaration of Helsinki and the local ethics committees
(EKBB – Ethikkommission beider Basel, Switzerland)
approved the protocol. All patients provided written
informed consent before participating in any protocol-
specific procedures.
Adjudication of the final diagnosis
The final diagnosis was independently adjudicated by two
gastroenterologists not involved in clinical of study patients
and blinded to calprotectin test results on the basis of all
available medical records pertaining to the individual pa-
tient (clinical data, laboratory values, endoscopy report,
histology report) according to current recommendations.
Senior gastroenterologists who were unaware of faecal test
results performed all endoscopies and findings were docu-
mented on a computer-based datasheet (ViewPoint, GE
Healthcare, Chalfont St Giles, U.K.).
Endpoint
The diagnostic value of calprotectin measurement and
guidelines of appropriateness were assessed in compari-
son to the presence of clinically significant findings at
endoscopy.
Assessing appropriateness of endoscopy
We used the European Panel on the Appropriateness of
Gastrointestinal Endoscopy (EPAGE) criteria to assess
the appropriateness of endoscopy. Briefly, members of a
multidisciplinary European expert panel examined exist-
ing evidence summarized in a comprehensive literature
review and rated the appropriateness of all possible indi-
cations for endoscopy in a series of clinical indications.
In each clinical scenario, the use of endoscopy was then
graded on a 9-point scale using the following scores: 1 =
extremely inappropriate, 5 = uncertain, 9 = extremely ap-
propriate. An indication for endoscopy was considered
appropriate if the median rating was between 7 and 9,
without disagreement, and inappropriate if the median
was between 1 and 3, without disagreement. Scenarios
with a median rating of 4 to 6, or those revealing dis-
agreement among the panellists were considered “uncer-
tain” as to the appropriateness of endoscopy in such
cases. A more detailed explanation of the methodology
and appropriateness ratings can be found elsewhere
[5,6].
In our study, we retrospectively assessed EPAGE
criteria for endoscopy in our population of patients
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computer-based algorithm, the appropriateness of endos-
copy was determined by two gastroenterologists blinded
to FC values. In case of disagreement, cases were reviewed
in conjunction with a third gastroenterologist who was
considered to be an expert in the field.
Thirty-four groups of indications for EGD and colon-
oscopy have been described in the EPAGE criteria. In
our study, patients were categorized in a predefined set
of clinical scenarios, according to their main symptoms
at presentation. If patients did not fit any of these criteria
or if insufficient data was available from chart review to
determine EPAGE criteria, patients were excluded from
the final analysis.Collection of faecal samples
All tests were performed on a single stool sample in all
patients. Patients were instructed to collect the sample
at home 24 hours prior to bowel preparation or endos-
copy. Samples were delivered on the day of the investi-
gation and stored in a refrigerator before transfer to the
study laboratory (Rothen Medical Laboratories, Basel,
Switzerland) within 48 hours for analysis. Calprotectin is
stable at room temperature for up to seven days. All fae-
cal samples were processed within 72 hours after collec-
tion. The laboratory personnel carrying out the analysis
was blinded to the clinical history, clinical data and the
endoscopic findings of the patients.Measurement of faecal calprotectin
Faecal calprotectin values were determined using a
commercially-available enzyme-linked immunosorbent assay
(ELISA) by Bühlmann Laboratories AG, Schönenbuch,
Switzerland. Senior laboratory personnel blinded to patient
history and calprotectin levels performed all analyses.
Aliquots of approximately 100 mg of faeces were ho-
mogenized in a 5 mL extraction buffer delivered with
the assay. 2 mL of the homogenate was then centrifuged
in a micro-centrifuge for 5 min at 3000 g and 100 μl of
the diluted supernatant (1:50 with incubation buffer)
were incubated at room temperature onto a microtiter
plate coated with a monoclonal capture antibody highly
specific to the calprotectin heterodimeric and polymeric
complexes. After incubation, washing and the addition
of a detection antibody coupled to horseradish peroxid-
ase, substrate was added and incubated, followed by
addition of a stop solution. The absorption rate was de-
termined at an optical density of 450 nm. The test mea-
sured concentrations from 10 to 600 μg calprotectin/g
feces with an intra- and inter-assay coefficient of 4.7%
and 4.1%, respectively. For quantification of higher cal-
protectin concentrations, additional dilutions of the ex-
tracts were done. The cut-off level representing apositive value was >50ug/g as recommended by the
manufacturer.
Endoscopy
All patients underwent standard endoscopy performed
by senior gastroenterologists who were unaware of faecal
calprotectin values at the time of the investigation. En-
doscopies were documented on a computer-based data-
sheet (ViewPoint, GE Healthcare, Chalfont St. Giles, U.
K.) that included a detailed description of the findings
by choosing from a predefined list and electronic storage
of all images taken during the investigation. Biopsies
were collected if appropriate as decided by the endosco-
pist. Patients with no significant lesion but with elevated
faecal calprotectin levels (> 50 μg/g) at initial endoscopy
were further investigated with either EGD or colonos-
copy. The endoscopist performing the follow-up endos-
copy was aware of the indication for the investigation
(positive test result).
Statistical analysis
Results of numerical data are presented as mean (standard
deviation, SD) or median (interquartile range, IQR) where
appropriate. The Mann–Whitney U-test (for two independ-
ent groups) and the Kruskal-Wallis H-test (for more than
two independent groups) were used to compare numerical
data and the chi-square test was used to compare categor-
ical data. Receiver operating characteristics analyses were
carried out to determine the test characteristics. Overall ac-
curacy was calculated according to the following formula:
(true positive test results + true negative test results)/total
population. Improvements in risk classification for signifi-
cant findings were evaluated using the net reclassification
improvement (NRI) method. Predicted probabilities for sig-
nificant findings on endoscopy for each patient were deter-
mined using the base model (EPAGE scoring). The NRI
represents the percentage change in predicted findings after
including a new marker in the base model. Owing to the
lack of established risk prediction models and given an ob-
served prevalence for significant findings at endoscopy of
36%, risk categories of <30%, 30 – 50% and >50% were
chosen for inappropriate, uncertain and appropriate endos-
copy from a clinical point of view. Model 1 included scor-
ing from EPAGE criteria; the new model 2 included faecal
calprotectin in addition to the EPAGE score as a continu-
ous parameter. An additive logistic regression model was
performed. The predicted values of the regression were
considered as a risk factor. Before evaluation, faecal calpro-
tectin values were log-transformed. We then categorized
patients according to their risk of significant endoscopic
findings and compared the proportion of patients whose
new prediction was improved with those whose prediction
became less accurate using the new model 2. A related par-
ameter, the integrated discrimination improvement (IDI),
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model with an additional marker by comparing average
predicted probabilities between patients with and without
significant findings of the two models without first categor-
izing the probabilities. A p-value <0.05 was considered to
be statistically significant. To visualize the estimate risks de-
pending on the predictors, nomograms were displayed. All
evaluations were done using R version 2.15.1 (R Core Team
(2012), Vienna, Austria. ISBN 3-900051-07-0, URL http://




Of 575 patients enrolled in the study, 298 patients
(51.8%) were available for analysis. Two hundred and
seventy-seven patients (48.2%) were excluded; in 177
patients data from chart review was insufficient to
calculate an EPAGE score, 63 patients could not be
adjudicated according to our predefined list EPAGE
algorithms and 37 patients were excluded for protocolFigure 1 Study flow. Study flow of patients referred for endoscopy. A tot
endoscopy, 31 patients because of protocol violation (no follow-up investig
patients because of insufficient data at chart review to calculate EPAGE sco
predefined list of EPAGE criteria. * Patients included in [22].violation (did not have follow-up investigation after
negative endoscopy and positive calprotectin test result)
or incomplete endoscopy (Figure 1). Baseline characteris-
tics are shown in Table 1. EGD was performed in 149
patients (50.0%) and 224 (75.2%) had colonoscopy. In
75 patients (25.2%) both procedures were performed.
Among the study population, the overall prevalence
of a significant lesion in the gastrointestinal tract was
36.2%, specifically 42.3% in the upper gastrointestinal
tract and 21.0% in the colon.
Appropriateness of endoscopy
Overall, 373 endoscopies were performed. Among the
predefined list of EPAGE indications, the investigation
of uncomplicated dyspepsia (N = 67, 44.9%) was the most
prevalent reason for performing EGD, while colonoscopy
was most often done for lower abdominal symptoms
(N = 114, 50.9%) (Table 2). Of 149 EGDs performed,
26 (17.4%) were for inappropriate indications, whereas
10 (6.7%) were for indications that were considered uncer-
tain and 113 (75.8%) were for appropriate indications.al of 277 patients were excluded: 6 patients because of incomplete
ation in normal endoscopy but faecal calprotectin > 50 μg/g), 244
re and 63 patients because they could not be assessed using the
Table 1 Baseline characteristics
Number of patients 298
Female patients, N (%) 164 (55.0%)
Age, years (IQR) 58 (46 – 67)
Colonoscopy, N (%) 224 (75.2%)
EGD, N (%) 149 (50.0%)
Colonoscopy and EGD, N (%) 75 (25.2%)
Data are presented as median (interquartile range, IQR) and number of
patients (%). EGD: esophagogastroduodenoscopy.
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were considered inappropriate, 51 (22.8%) were judged
uncertain and 140 (62.5%) were done for appropriate
indications. Table 2 gives a detailed overview. The
investigation of uncomplicated dyspepsia showed the
highest rate of inappropriate indications (29.9%), whereas
the investigation of alarm symptoms was done for an
appropriate indication in a majority of patients (97.8%).
Overall, the rate of inappropriate indications for endoscopy
was 15.8%.
Diagnostic yield in inappropriate, uncertain and
appropriate endoscopy
Using EPAGE criteria, diagnostic yield for clinically sig-
nificant lesions was higher in patients with appropriate
or uncertain indications than in those with an inappro-
priate indication for endoscopy (32.5% vs. 13.6%, P =
0.006). EGD revealed significant findings in 46.3% of ap-
propriate or uncertain indications compared to 23.1% in
inappropriate indications (P = 0.049). Similarly, signifi-
cant findings during colonoscopy were more prevalent
in patients with appropriate or uncertain indications




Frequent symptoms suggesting reflux disease 27










Data are presented as numbers (%). Miscellaneous indications for EGD included 8 p
6 patients with metastases that required further evaluation, 2 patients with iron-defP = 0.041). Endoscopic findings and corresponding ap-
propriateness ratings are given in Table 3.
Diagnostic value of faecal calprotectin
Median calprotectin levels were higher in patients
with significant findings (N = 108, median 81.5 μg/g,
IQR 26 – 175 μg/g) than in patients without such
findings (N = 190, 10 μg/g, IQR 10 – 22, P < 0.001).
Using evaluation of faecal calprotectin as a diagnostic
test, we found an area under the receiver operating
characteristics curve (AUC) of 0.846 (95% confidence
interval (CI), 0.80 – 0.89), specifically an AUC of
0.642 (0.56 – 0.72) for EGD and an AUC of 0.863
(0.81 – 0.91) for colonoscopy (Figure 2). Using the
optimal cut-off value (58 μg/g for EGD and 38 μg/g
for colonoscopy), faecal calprotectin yielded a sensitivity
and specificity of 49.2% and 74.4% for EGD and
72.3% and 88.7% for colonoscopy, respectively. Thus,
patients with positive calprotectin test results (> 50 μg/g
according to the manufacturer) more often had significant
findings at endoscopy, both at EGD (58.2% vs. 34.1%,
P = 0.005) and at colonoscopy (57.4% vs. 7.4%, P < 0.001).
Incremental value of calprotectin to EPAGE criteria
The use of faecal calprotectin in addition to EPAGE cri-
teria improved the reclassification of patients in terms of
risk of significant findings at endoscopy (Tables 4 and 5).
Amongst patients with normal EGD, 46 patients (63%)
were correctly reclassified as at lower risk of endoscopic
findings and 4 patients (5.5%) were incorrectly reclassi-
fied as at higher risk. Amongst patients with significant
findings at EGD, 11 patients (14.5%) were correctly re-
classified as at higher risk of endoscopic findings and 26
patients (34.2%) were incorrectly reclassified as at lowerInappropriate Uncertain Appropriate
26 (17.5%) 10 (6.7%) 113 (75.8%)
20 (29.9%) 7 (10.4%) 40 (59.7%)
5 (18.5%) 2 (7.4%) 20 (74.1%)
1 (100.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 1 (2.2%) 45 (97.8%)
0 (0.0%) 0 (0.0%) 8 (100%)
33 (14.7%) 51 (22.8%) 140 (62.5%)
2 (8.0%) 8 (32.0%) 15 (60.0%)
1 (1.6%) 7 (11.5%) 53 (86.9%)
28 (24.6%) 36 (31.6%) 50 (43.8%)
1 (6.7%) 0 (0.0%) 14 (93.3%)
1 (11.1%) 0 (0.0%) 8 (88.9%)
59 (15.8%) 61 (16.4%) 253 (67.8%)
atients with celiac disease; miscellaneous indications for colonoscopy included
iciency without anaemia and 1 patient with perianal fistula.
Table 3 Diagnostic yield of endoscopy
Endoscopic findings N Inappropriate Uncertain Appropriate
No significant findings 261 51 (19.6%) 45 (17.2%) 165 (63.2%)
Clinically-significant findings 112 8 (7.1%) 16 (14.3%) 88 (78.6%)
Reflux esophagitis 44 5 (11.3%) 2 (4.6%) 37 (84.1%)
Erosive gastritis 13 1 (7.7%) 1 (7.7%) 11 (84.6%)
Gastric ulcer 4 0 (0.0%) 0 (0.0%) 4 (100%)
Stomach cancer 2 0 (0.0%) 1 (50%) 1 (50%)
Inflammatory bowel disease 9 0 (0.0%) 4 (44.4%) 5 (55.6%)
Infectious colitis 4 0 (0.0%) 0 (0.0%) 4 (100%)
Adenomatous polyp 20 1 (5.0%) 4 (20.0%) 15 (75.0%)
Colonic cancer 10 0 (0.0%) 2 (20.0%) 8 (80.0%)
Miscellaneous 6 1 (16.7%) 2 (33.3%) 3 (50.0%)
Data are presented as numbers (%). Reflux esophagitis included Los Angeles grade A (N = 22), grade B (N = 11), grade C (N = 3) and grade D (N = 8). Inflammatory
bowel disease included Crohn’s disease (N = 4) and ulcerative colitis (N = 5). Miscellaneous included diverticulitis (N = 2), NSAID-induced colitis (N = 2) and
unspecified proctitis (N = 2).
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37.8% (P 0.002) and absolute integrated discrimination
index (IDI) was 0.18 (P < 0.001). For colonoscopy, 100
patients (66.7%) with normal findings were correctly re-
classified as at lower risk for endoscopic lesions and 12
patients (8.0%) were incorrectly reclassified as at higher
risk. Amongst patients with significant findings, 49 pa-
tients (66.2%) were correctly reclassified as at higher risk
for endoscopic findings and 11 patients (14.9%) wereFigure 2 Diagnostic performance of faecal calprotectin testing.
Receiver-operating characteristic (ROC) curve for clinically significant
findings during EGD (dotted line) and colonoscopy (solid line). We
also report the accuracy values for EPAGE criteria (EGD: open circle,
colonoscopy: solid circle). The ROC curve represents the relationship
between sensitivity and specificity for a considered outcome. EPAGE,
European Panel on the Appropriateness of Gastrointestinal Endoscopy.incorrectly reclassified as at lower risk. The calculated
NRI was 110.9% (P <0.001) and the absolute IDI was
0.41 (P <0.001). Figures 3 and 4 show nomograms of
EPAGE scoring and faecal calprotectin values to predict
the risk of significant findings at endoscopy. Using
EPAGE criteria in conjunction with faecal calprotectin
testing increased diagnostic yield (56.8% for EGD; 70.2%
for colonoscopy) compared to EPAGE criteria (46.3%
and 23.6%, respectively), and measurement of faecal cal-
protectin alone, especially for colonoscopy (58.2% and
57.4%, respectively).
Discussion
This post-hoc analysis of a prospective cohort of patients
with abdominal discomfort undergoing upper and lower
GI endoscopy examined the value of the European Panel
on the Appropriateness of Gastrointestinal Endoscopy
(EPAGE) criteria and faecal calprotectin testing on diag-
nostic yield. Specifically, we investigated if the addition
of faecal calprotectin testing would decrease the rate of
inappropriate endoscopies and increase diagnostic yield.
We report the following findings: First, the rate of in-
appropriate endoscopies in our study was slightly lower
than in most studies reported in the literature, owing to
the fact that only symptomatic patients were included.
Second, the diagnostic yield of clinically significant find-
ings was higher for appropriate than for inappropriate
endoscopies, both for EGD and colonoscopy, confirming
prior findings [7,9,11,12,15-18]. Third, faecal calprotectin
testing provided a significant added value to the ability
to detect significant findings throughout the gut while
performing less accurately in the upper intestinal tract.
Accordingly, diagnostic yield was significantly higher in
patients with elevated calprotectin values. Fourth, faecal
calprotectin testing improved risk stratification in patients
Table 4 Reclassification of patients with normal and clinically significant findings undergoing EGD by means of faecal
calprotectin measurement
EGD Endoscopic finding probability model 2 including EPAGE criteria and faecal
calprotectin values
Probability of findings <30% 30-50% >50% Total
Endoscopic finding probability model 1 including EPAGE criteria No findings
<30% 0 0 0 0
30-50% 13 6 4 23
>50% 6 27 17 50
Total 19 33 21 73
Significant findings
<30% 0 0 0 0
30-50% 3 0 11 14
>50% 2 21 39 62
Total 5 21 50 76
Amongst patients with normal EGD, 46 patients (63.0%) were correctly reclassified as at lower risk of endoscopic findings and 4 patients (5.5%) were incorrectly
reclassified as at higher risk. Amongst patients with significant findings at EGD, 11 patients (14.5%) were correctly reclassified as at higher risk of significant
findings and 26 patients (34.2%) were incorrectly reclassified as at lower risk. The calculated net reclassification index (NRI) was 37.8% (P 0.002).
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criteria. The NRI was 37.8% and 110.9% and the absolute
IDI was 0.18 and 0.41 for patients undergoing EGD and
colonoscopy, respectively. Therefore, our data support the
use of faecal calprotectin testing in conjunction with
EPAGE criteria in selecting the right patients for endos-
copy. The integration of calprotectin values in appropri-
ateness algorithms would likely increase diagnostic yield
of endoscopic investigations.
The number of endoscopic procedures, especially
colonoscopies, performed is steadily increasing, both in
Europe and the USA [23,24]. In the light of limited
resources and ever-increasing health-care costs, optimizing
the appropriate selection of patients for endoscopy isTable 5 Reclassification of patients with normal and clinically














Amongst patients with normal colonoscopy, 100 patients (66.7%) were correctly rec
incorrectly reclassified as at higher risk. Amongst patients with significant findings a
of endoscopic findings and 11 patients (14.9%) were incorrectly reclassified as at locrucial. Unfortunately, patient selection based on
symptoms alone is not suitable [1,2,25] and physicians
traditionally rely on clinical signs, laboratory data, expert
knowledge of the literature and personal experience to
decide whether endoscopy has to be performed.
In an effort to improve the appropriate use of endoscopy
and ultimately increase diagnostic yield, the multidisciplin-
ary European Panel on the Appropriateness of Gastrointes-
tinal Endoscopy (EPAGE) has developed guidelines for a
series of clinical scenarios [5,6]. Inappropriate EGDs and
colonoscopies are associated with lower diagnostic yield,
procedural risks for no apparent health benefit and longer
waiting periods in endoscopy units. The rate of inappropri-
ate endoscopies in our study population was 15.8%,significant findings undergoing colonoscopy by means
ic findings probability model 2 including EPAGE criteria and faecal
in values
y of findings <30% 30-50% >50% Total
25 1 1 27
100 13 10 123
0 0 0 0
125 14 11 150
findings
4 0 6 10
11 10 43 64
0 0 0 0
15 10 49 74
lassified as at lower risk for endoscopic lesions and 12 patients (8.0%) were
t colonoscopy, 49 patients (66.2%) were correctly reclassified as at higher risk
wer risk. The calculated NRI was 110.9% (P <0.001).
Figure 3 Nomogram for risk prediction of clinically significant findings by means of EPAGE criteria and faecal calprotectin values for
EGD. Nomograms of EPAGE scoring and log10 faecal calprotectin values to predict the risk of significant findings at EGD. Points for EPAGE scoring
and faecal calprotectin values (ug/g) are added to a total score, which will indicate the predicted risk (%) for endoscopic findings.
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was slightly lower than inappropriate rates reported by
most studies ranging from 19.5% to 39% [7,8] for EGD and
10.5% to 27% for colonoscopy [9-18]. However, the type of
criteria used and patients included may render direct com-
parison of inappropriateness rates difficult. In our study
which included only symptomatic patients, inappropriate
endoscopies were most often done for uncomplicated dys-
pepsia (29.9%) and lower abdominal symptoms (24.6%).
By linking clinical indications and endoscopic findings,
diagnostic yield can be determined and the prevalence of
endoscopic findings may differ significantly depending
on the indication. For example, colonoscopy for gastro-
intestinal bleeding (haematochezia, iron-deficiency an-
aemia, melena) will detect more colorectal cancers (1 in
9 to 13 endoscopies) than in patients without signs of
bleeding (1 in 109 colonoscopies) [26]. Similarly, diag-
nostic yield of significant findings in screening patients
is low (14.4%) [10]. Available data on the prevalence of
significant findings in patients referred for diagnostic
endoscopy in an open-access system such as that which
exists in Switzerland [7,10-12,15,17] show the following:
EGD judged appropriate or uncertain yielded significantly
more relevant lesions (60%) than those judged inappropriate
(37%) [7]. In patients referred for colonoscopy, appropriateFigure 4 Nomogram for risk prediction of clinically significant findings
colonoscopy. Nomograms of EPAGE scoring and log10 faecal calprotectin va
EPAGE scoring and faecal calprotectin values (ug/g) are added to a total scoreor uncertain indications had more relevant endoscopic
findings than those with inappropriate indications
(42% vs. 21% [11], 38.8% vs. 24.5% [12], 39.2% vs
13.4% [13], 74% vs. 16% [15], 25.6% vs. 17.6% [17])
and adherence to EPAGE recommendations was an
independent predictor of significant findings (OR 1.93)
[12]. In addition, alarm symptoms are not effective predic-
tors of endoscopic findings [27-29]. Major pathologies were
found in only 21% (787 of 3815) of upper endoscopies [3]
and 42% of EGDs performed for severe alarm symptoms
such as dysphagia or hematemesis did not result in
pathological findings [30]. In a model incorporating
three Manning criteria and alarm features yielded a
correct diagnosis of IBS in 96% and a correct diagnosis of
organic disease in 52% of cases [29]. Similarly, alarm
features did not discriminate functional dyspepsia
from upper gastrointestinal disease. Vakil et al. showed in
their systematic review and meta-analysis, that alarm
symptoms have a low positive predictive value for malig-
nancy at EGD [27]. If alarm symptoms are present, the
likelihood of an upper GI malignancy increases slightly,
but the absolute increase remains small. The negative pre-
dictive will be high, but this reflects the low prevalence of
cancer in dyspeptic patients. In patients with constipation,
the risk of a significant finding at colonoscopy was notby means of EPAGE criteria and faecal calprotectin values for
lues to predict the risk of significant findings at colonoscopy. Points for
, which will indicate the predicted risk (%) for endoscopic findings.
Burri et al. BMC Gastroenterology 2014, 14:57 Page 9 of 11
http://www.biomedcentral.com/1471-230X/14/57increased and if present alone, the risk was lower than for
average-risk screening colonoscopy [31]. Even when
haematochezia was present, colonoscopy in patients with
a “low and average risk” for colorectal cancer showed
abnormal findings in only 34% of younger (age <45 years)
compared to 66% in older patients [4].
Data from our study confirms previous results by
showing a higher diagnostic yield in appropriate com-
pared to inappropriate investigations both for EGD and
colonoscopy. Also, the overall prevalence of clinically-
significant findings in our study population was 36.2%
(EGD 43.2%, colonoscopy 21.0%) and comparable to
findings by others for EGD (30 – 52%) [7,8,15,30] and
colonoscopy (14.4 – 41%) [10-13,17,18].
Unfortunately, the association between appropriate-
ness criteria and the detection of significant lesions is
less than perfect such as is the relationship between clin-
ical symptoms and endoscopic diagnosis, even in pa-
tients with clinical signs suggesting organic disease, e.g.
patients with haematochezia, chronic diarrhoea or con-
stipation. Relevant endoscopic findings are detected in a
considerable proportion of inappropriate EGDs and col-
onoscopies [7,8] and diagnostic yield in appropriate en-
doscopies is <50% in most studies. As a result, nearly
one in every two patients with an appropriate indication
will have a normal examination [32]. Improving diagnos-
tic yield of endoscopies is therefore highly desirable.
In our study, we measured faecal calprotectin as an
additional biomarker to improve diagnostic yield in
symptomatic patients referred for endoscopy in an
open-access system. Patients with endoscopic findings
more often had positive faecal calprotectin testing than
patients with normal findings and as a stand-alone test,
it was useful in identifying organic intestinal disease, es-
pecially in the colon. It has been shown, that the diag-
nostic value of fecal calprotectin is not limited to the
colon [22,33] and may have an important role to guide
endoscopic investigations, especially if elevated calpro-
tectin levels are found in conjunction with a normal col-
onoscopy. However, in a number of organic intestinal
diseases, e.g. chronic gastritis, small intestinal bacterial
overgrowth and celiac disease, fecal calprotectin is not
elevated [34-36]. In our study, only patients with muco-
sal breaks were classified as significant findings.
Using faecal calprotectin testing in conjunction with
EPAGE criteria scores led to a significant reclassification
of patients being correctly classified as at higher or lower
risk of endoscopic findings than did assessment with ap-
propriateness criteria alone. The use of faecal calprotec-
tin testing as a continuous rather than a categorical
parameter (below or above cut-off of 50 ug/g) allowed
for a detailed risk stratification of individual patients
presenting with abdominal complaints. We estimated
the risk for endoscopic findings to be <30% in patientswith inappropriate indications for endoscopy. Accord-
ingly, in patients that would require endoscopy accord-
ing to the risk prediction, diagnostic yield increased
compared to the individual use of EPAGE scoring or fae-
cal calprotectin values, especially for colonoscopy.
The clinical implications of our study merit consider-
ation. The combined use of EPAGE scoring and faecal
calprotectin testing led to a superior risk stratification in
patients with abdominal complaints and increased diag-
nostic yield in patients requiring endoscopy. This would
especially be useful in open-access health care systems,
when patients are referred for endoscopy by non-
gastroenterologists. The use of an objective, easy-to-use
and easy-to-interpret biomarker would decrease the rate
of, often unintentionally, inappropriate endoscopies, and
would facilitate the decision to perform endoscopy when
the indication is driven by the patient’s (or the doctor’s)
fear of missing a diagnosis rather than by rational clin-
ical judgment. Accordingly, our data indicate that faecal
calprotectin testing should be included in the current
EPAGE algorithms or other algorithms devoted to clin-
ical decision-making as to when to perform digestive en-
doscopy. However, it remains to be determined at what
stage of the decision tree the diagnostic impact of faecal
calprotectin testing would be greatest. Additionally, future
studies should also aim to investigate the cost-effectiveness
of appropriateness guidelines, especially when costs of
additional biomarkers are taken into account.
There are several potential limitations of the current
study. First, this was a post-hoc analysis of a prospective
study and EPAGE criteria were applied retrospectively. It
has been shown that retrospective analysis of appropri-
ateness criteria is feasible but is found to be imprecise
when adjudicating patients to certain indication groups
[37]. Second, we carefully assessed the appropriateness
of endoscopies using a predefined list of indications and
we meticulously reviewed all available data of each
individual patient to include only those with sufficient
clinical and laboratory information. Of 575 patients
originally enrolled, only 51.8% were available for ana-
lysis, thus making the analysis susceptible to selection
bias. However, when baseline characteristics of patients
excluded were compared, patients in the study population
were younger and had received more EGDs and fewer
colonoscopies but the prevalence of significant endoscopic
findings was similar (Additional file 1: Table S1). Third,
EPAGE appropriateness guidelines are panel-based opinions
and thus present an inherent limitation. Guidelines should
be regarded as recommendations but cannot fully replace
clinical judgment, especially at an individual level. However,
clinical judgment alone is unreliable in predicting organic
intestinal disease and hence is an insufficient indicator for
assessing appropriateness of GI endoscopy. In addition,
gastroenterologists overestimate the appropriateness of
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for significant endoscopic findings in inappropriate, uncer-
tain and appropriate endoscopy according to EPAGE
criteria are unknown, the reclassification of patients in this
study was based on estimated risk-groups. The estima-
tions were based on the available data on diagnostic yield
found in the literature of patients with inappropriate,
uncertain and appropriate indications for endoscopy
according to EPAGE criteria [7,8,10-14]. Fifth, data
derived from a single-centre study always need to be
replicated in larger, multi-centre studies.Conclusion
In conclusion, our study showed that measurement of
faecal calprotectin is useful for identifying clinically-
significant endoscopic findings in patients with abdominal
complaints and when combined with appropriateness
guidelines improves the limited diagnostic yield of EPAGE
criteria. Larger, prospective studies should investigate if the
use of faecal calprotectin testing, possibly in combination
with other biomarkers, would warrant inclusion in diagnos-
tic algorithms such as EPAGE guidelines.Additional file
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